David Dworaczyk

David, like Michelle, suffers from a life-threatening allergy, in his case bee stings. When he listened to her concerns about her twins, he knew first hand that her vision was right on target. Now, David is working tirelessly to create A Better Way for people at risk for anaphylaxis. Dr. Dworaczyk has over 35 years of experience in the pharmaceutical, biotechnology, molecular diagnostic, medical device and CRO industry where he has held senior level positions in R&D, Global Operations, Business Development (L&A/M&A), Clinical Development, Strategic Planning, Project Management, Commercial Operations and healthcare analytics. Prior to joining Bryn Pharma, he directed the Life and Health Sciences Strategic Development effort at Oracle. He has also served as COO for Comprehensive Clinical Development, Sr. Vice President, General Manager & COO at Generation Health/MetaDiagnostic, a start-up focused on molecular diagnostics, genomics and personalized medicine, was COO for The Moffitt Cancer Center/M2Gen (for-profit subsidiary) and Sr. VP at Quintiles. Dr. Dworaczyk's experience is broad and he has had global responsibilities including leading operational functions across multiple business units, genomics/biomarkers, translational research, patient targeted drug development, gene based trial matching, translational research, precision/personalized medicine, healthcare analytics/informatics, population health as well as the integration and effective use of Real World Data/Evidence and “Big/Complex” data. David earned a B.S and M.S in Molecular Biology from the State University of New York at Buffalo and a PhD in Leadership and Administration from the University of Delaware.

Bryn Pharma